Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
The third trial to report in this space was TALAPRO-2. Dr. Aggarwal presented the all-comers cohort from this trial at ASCO-GU this spring with the manuscript (highlighted here) subsequently published. Designed in much the same way as PROpel, this cohort of the TALAPRO-2 trial demonstrated significantly improved radiographic progression-free survival among all-comers with mCRPC receiving first-line treatment with talazoparib plus enzalutamide, compared to enzalutamide. To date, overall survival data remain immature.
